Michael F. Drummond

• ABPI
• Health Policy and Regulation
• Orphan Drugs
• Pricing and Reimbursement
• Rare and Orphan Diseases
• UK

Establishing a Reasonable Price for an Orphan Drug

Read more

• Cancer
• Clinical Outcomes
• Oncology

Using QALYs in Cancer: Review of the Methodological Limitations

Read more

• Cancer
• HTA
• NICE
• Oncology
• Health Technology Assessment…

Assessment and Appraisal of Oncology Medicines: NICE’s Approach and International HTA Experience

Read more

• Germany
• HTA
• UK
• Health Technology Assessment…

New Guidelines for Economic Evaluation in Germany and the United Kingdom: Are We Any Closer to Developing International Standards?

Read more

• Real World Evidence (RWE)

Economic Post-Launch Studies: Matching the Desirable with the Feasible

Read more